Exponent (NASDAQ:EXPO) VP Sells $117,059.56 in Stock

Exponent, Inc. (NASDAQ:EXPO) VP Joseph Sala sold 2,066 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $56.66, for a total value of $117,059.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Exponent Trading Up 0.2%

NASDAQ EXPO opened at $53.79 on Friday. The business’s 50-day moving average price is $65.71 and its two-hundred day moving average price is $69.74. Exponent, Inc. has a 12 month low of $51.91 and a 12 month high of $81.95. The firm has a market capitalization of $2.61 billion, a PE ratio of 25.02 and a beta of 0.78.

Exponent (NASDAQ:EXPO) last released its quarterly earnings results on Thursday, April 30th. The business services provider reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. Exponent had a return on equity of 27.94% and a net margin of 18.07%.The firm had revenue of $166.30 million for the quarter, compared to analyst estimates of $149.53 million. During the same quarter in the previous year, the company posted $0.52 EPS. The business’s revenue was up 14.3% on a year-over-year basis. As a group, analysts forecast that Exponent, Inc. will post 2.28 earnings per share for the current fiscal year.

Exponent Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Friday, June 5th will be given a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, June 5th. Exponent’s payout ratio is 57.67%.

Analyst Ratings Changes

EXPO has been the topic of a number of recent analyst reports. UBS Group dropped their price objective on Exponent from $85.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, May 1st. JPMorgan Chase & Co. dropped their price objective on Exponent from $95.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Exponent in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $77.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in EXPO. Bell Investment Advisors Inc lifted its stake in shares of Exponent by 423.6% in the 1st quarter. Bell Investment Advisors Inc now owns 377 shares of the business services provider’s stock valued at $25,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. lifted its stake in shares of Exponent by 97.0% in the 3rd quarter. Hantz Financial Services Inc. now owns 396 shares of the business services provider’s stock valued at $28,000 after purchasing an additional 195 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Exponent during the 3rd quarter worth approximately $33,000. Allworth Financial LP boosted its holdings in Exponent by 86.1% in the fourth quarter. Allworth Financial LP now owns 469 shares of the business services provider’s stock worth $33,000 after acquiring an additional 217 shares in the last quarter. Finally, Winnow Wealth LLC bought a new position in Exponent in the third quarter worth approximately $34,000. 92.37% of the stock is owned by institutional investors and hedge funds.

Exponent Company Profile

Exponent, Inc (NASDAQ: EXPO) is an engineering and scientific consulting firm that offers multidisciplinary analysis and advisory services to clients across a range of industries. The company’s expertise spans mechanical, materials and corrosion engineering, civil and structural engineering, electrical engineering, industrial hygiene, toxicology and health sciences, and failure analysis. Exponent provides support for product design, performance evaluation, litigation consulting, and regulatory compliance, helping manufacturers, insurers, law firms and government agencies address complex technical challenges.

Founded in 1967 in Menlo Park, California, Exponent has grown from a small failure-analysis laboratory into a global consulting practice.